State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu, P. R. China.
Department of Pharmacology, and Provincial Key Laboratory of Pathophysiology in Ningbo University School of Medicine, Ningbo, Zhejiang, China.
Proteomics Clin Appl. 2022 Nov;16(6):e2100097. doi: 10.1002/prca.202100097. Epub 2022 May 11.
In the context of precision medicine, disease treatment requires individualized strategies based on the underlying molecular characteristics to overcome therapeutic challenges posed by heterogeneity. For this purpose, it is essential to develop new biomarkers to diagnose, stratify, or possibly prevent diseases. Plasma is an available source of biomarkers that greatly reflects the physiological and pathological conditions of the body. An increasing number of studies are focusing on proteins and peptides, including many involving the Human Proteome Project (HPP) of the Human Proteome Organization (HUPO), and proteomics and peptidomics techniques are emerging as critical tools for developing novel precision medicine preventative measures. Excitingly, the emerging plasma proteomics and peptidomics toolbox exhibits a huge potential for studying pathogenesis of diseases (e.g., COVID-19 and cancer), identifying valuable biomarkers and improving clinical management. However, the enormous complexity and wide dynamic range of plasma proteins makes plasma proteome profiling challenging. Herein, we summarize the recent advances in plasma proteomics and peptidomics with a focus on their emerging roles in COVID-19 and cancer research, aiming to emphasize the significance of plasma proteomics and peptidomics in clinical applications and precision medicine.
在精准医学的背景下，疾病的治疗需要根据潜在的分子特征制定个体化策略，以克服异质性带来的治疗挑战。为此，开发新的生物标志物来诊断、分层或可能预防疾病至关重要。血浆是生物标志物的一个可用来源，它极大地反映了身体的生理和病理状况。越来越多的研究集中在蛋白质和肽上，包括许多涉及人类蛋白质组组织（HUPO）的人类蛋白质组计划（HPP），蛋白质组学和肽组学技术正成为开发新型精准医学预防措施的关键工具。令人兴奋的是，新兴的血浆蛋白质组学和肽组学工具包在研究疾病的发病机制（如 COVID-19 和癌症）、识别有价值的生物标志物和改善临床管理方面显示出巨大的潜力。然而，血浆蛋白质的巨大复杂性和广泛的动态范围使得血浆蛋白质组学分析具有挑战性。本文总结了血浆蛋白质组学和肽组学的最新进展，重点介绍了它们在 COVID-19 和癌症研究中的新兴作用，旨在强调血浆蛋白质组学和肽组学在临床应用和精准医学中的重要性。
